Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FB3KW
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,929
Award facts
- Contract value 100% obligated
- $18,929.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,929.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml auto-injectors. The contract, awarded on September 4, 2025, with an ultimate completion date of September 5, 2025, represents a direct fulfillment order under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA. This delivery order carries no set-aside designation, allowing the company to compete on an unrestricted basis despite its woman-owned small business status. The product will be delivered to Park Ridge, Illinois, supporting the Defense Logistics Agency's pharmaceutical supply chain operations.
DMS Pharmaceutical Group holds a significant single-award IDC with the Defense Logistics Agency valued at $499.999 billion and valid through November 2026 under the SPE2DB program, positioning the company as a critical supplier for military health facility pharmaceutical needs. The company's federal contracting portfolio demonstrates extensive experience delivering a comprehensive range of prescription medications, biologics, and medical consumables to Department of Defense healthcare sites nationwide. Nucala, a biologic auto-injector typically used for severe eosinophilic asthma and certain allergic conditions, represents one of many specialized pharmaceutical products the company supplies through its DLA contract vehicle.
Quick answers
Who was awarded contract SPE2DB25FB3KW?
SPE2DB25FB3KW was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 4, 2025.
How much is contract SPE2DB25FB3KW worth?
The government has obligated $18,929 on SPE2DB25FB3KW.
Is contract SPE2DB25FB3KW an order under another contract?
Yes. SPE2DB25FB3KW is a delivery order under SPE2DB20D9761, an indefinite delivery contract.
Was contract SPE2DB25FB3KW competed?
The extent of competition for SPE2DB25FB3KW was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award